Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with CKD

Sponsor
Tor Biering-Sørensen
Study ID
NCT05359263
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Chronic Kidney Diseases

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Dapagliflozin 10 mg — DRUG
    The intervention arm consists of dapagliflozin 10 mg orally once daily
  • Placebo — DRUG
    The comparator arm consists of placebo orally once daily

Study Details

The purpose of this study is to investigate the effects of dapagliflozin on echocardiographic measures of cardiac structure and function in patients with chronic kidney disease.

Key Dates

Start date
Jun 8, 2022
Status verified
Feb 2025
Primary completion
Feb 18, 2025
Completion
Feb 18, 2025

Study Design

Enrollment
222 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Dapagliflozin 10 mg once daily
  • Placebo Comparator: Placebo once daily

Primary Outcome Measure

Change in LV mass index assessed by echocardiography at 6 months [ Time Frame: 6 months ]

Central Contacts

Related Studies